Low-sorbing glyburide formulation and methods
Methods and formulations for minimizing or avoiding the sorption of glyburide to surfaces of delivery tubing, filters, bags, and other containers and materials, thereby storing and delivering a more stable product, delivering a predictable and accurate dose of glyburide, while minimizing impurities, avoiding drug waste, reducing cost, and significantly reducing the amount of dosing solution that must be infused into the patient.
1 . A lyophilized formulation of glyburide in a vial comprising:
a) glyburide or a pharmaceutically acceptable salt thereof;
b) a buffering agent;
c) a base;
d) a sugar alcohol, and
wherein the lyophilized formulation has a pH outside of the buffering capacity of the buffering agent when reconstituted in water for injection (WFI),
wherein the buffering agent has a pKa of 7.7 to 9.2,
wherein the lyophilized formulation comprises the sugar alcohol and the glyburide or pharmaceutically acceptable salt thereof in a weight ratio of 27 to 40:1, and/or comprises the base and the glyburide or pharmaceutically acceptable salt therein in a molar ratio of 5.4 to 6.3:1,
wherein the lyophilized formulation is free of cyclodextrins, and
wherein the vial contains about 4 mg of the glyburide or pharmaceutically acceptable salt thereof.
2 . The lyophilized formulation of claim 1 , wherein the pharmaceutically acceptable salt thereof is a sodium addition salt.
3 . The lyophilized formulation of claim 1 , wherein the glyburide or pharmaceutically acceptable salt thereof is about 2.7 to 3.1% (w/w) of the lyophilized formulation.
4 . The lyophilized formulation of claim 1 , wherein the sugar alcohol is about 84 to 90% w/w of the lyophilized formulation.
5 . The lyophilized formulation of claim 1 , comprising the sugar alcohol and the glyburide or pharmaceutically acceptable salt thereof in a weight ratio of 28 to 35:1.
6 . The lyophilized formulation of claim 1 , wherein, upon storage for 12 months at 25° C./60% relative humidity (RH), has a pH when reconstituted in WFI that is within about 0.2 pH unit of the lyophilized formulation when reconstituted in WFI prior to storage, or wherein, upon storage for 6 months at 40° C./75% RH, has a pH when reconstituted in WFI that is within about 0.2 pH unit of the lyophilized formulation when reconstituted in WFI prior to storage, or wherein, upon storage for 4 weeks at 70° C./75% RH, has a pH when reconstituted in WFI that is within about 0.2 pH unit of the lyophilized formulation when reconstituted in WFI prior to storage.
7 . The lyophilized formulation of claim 1 , wherein the buffering agent is a buffer having a pH of 7.8 to 9.
8 . The lyophilized formulation of claim 1 , wherein the lyophilized formulation has a pH of 10.1 to 10.9 when reconstituted in water for injection (WFI).
9 . The lyophilized formulation of claim 1 , wherein the lyophilized formulation comprises the sugar alcohol and the glyburide or pharmaceutically acceptable salt thereof in a weight ratio of 27 to 40:1.
10 . The lyophilized formulation of claim 1 , wherein the lyophilized formulation comprises the sugar alcohol and the buffering agent in a weight ratio of 8 to 12:1.
11 . The lyophilized formulation of claim 1 , wherein the lyophilized formulation comprises 26 to 34 mg/ml of the sugar alcohol when reconstituted in WFI.
12 . The lyophilized formulation of claim 1 , wherein the base and the glyburide or pharmaceutically acceptable salt thereof have a molar ratio of 5.4 to 6.3:1.
13 . The lyophilized formulation of claim 1 , wherein the lyophilized formulation comprises about 8 to 12% (w/w) of the buffering agent.
14 . A liquid intravenous (IV) formulation comprising:
a) glyburide or a pharmaceutically acceptable salt thereof;
b) a buffering agent;
c) a base;
d) a sugar alcohol, and
wherein the liquid IV formulation has a pH outside of the buffering capacity of the buffering agent,
wherein the liquid IV formulation comprises the sugar alcohol and the glyburide or pharmaceutically acceptable salt thereof in a weight ratio of 27 to 40:1, and/or comprises the base and the glyburide or pharmaceutically acceptable salt thereof in a molar ratio of 5.4 to 6.3:1, and wherein the liquid IV formulation is free of cyclodextrins.
15 . The liquid IV formulation of claim 14 , comprising the sugar alcohol and the glyburide or pharmaceutically acceptable salt thereof in a weight ratio of 28 to 35:1.
16 . The liquid IV formulation of claim 14 , wherein the buffering agent is a buffer having a pH of 7.8 to 9.
17 . The liquid IV formulation of claim 14 , wherein the liquid IV formulation has a pH of 7.8 to 9.
18 . The liquid IV formulation of claim 14 , wherein the liquid IV formulation comprises the sugar alcohol and the glyburide or pharmaceutically acceptable salt thereof in a weight ratio of 27 to 40:1.
19 . The liquid IV formulation of claim 14 , wherein the liquid IV formulation comprises the sugar alcohol and the buffering agent in a weight ratio of 8 to 12:1.
20 . The liquid IV formulation of claim 14 , wherein the liquid IV formulation comprises 26 to 34 mg/ml of the sugar alcohol.
21 . The liquid IV formulation of claim 14 , wherein the base and the glyburide or pharmaceutically acceptable salt thereof have a molar ratio of 5.4 to 6.3:1.
22 . A kit for making a liquid IV formulation, the kit comprising a first container comprising a lyophilized formulation and an admixture device configured to reconstitute and transfer the lyophilized formulation between the first container and a second container prior to administration, wherein the lyophilized formulation comprises:
a) glyburide or a pharmaceutically acceptable salt thereof;
a buffering agent;
a base;
d) a sugar alcohol, and
23 . The kit of claim 22 , wherein the glyburide or a pharmaceutically acceptable salt thereof is 0.2 to 10.8 wt % of the lyophilized formulation; the buffering agent is 4.4 to 8.8 wt % of the lyophilized formulation; and the sugar alcohol is 80.1 to 94 wt % of the lyophilized formulation.
24 . The liquid IV formulation of claim 14 , wherein the liquid IV formulation has a pH of 7.8 to 9, and the pH of the liquid IV formulation does not change by more than 0.2 pH units over the course of a 24 hour infusion.
25 . A liquid infusion composition comprising a saline solution and a lyophilized formulation, wherein the lyophilized formulation comprises:
a) glyburide or a pharmaceutically acceptable salt thereof;
) a buffering agent;
a base;
d) a sugar alcohol, and
26 . The liquid infusion composition of claim 25 , wherein the liquid infusion composition has a pH of 7.8 to 9, and the pH of the liquid infusion composition does not change by more than 0.2 pH units over the course of a 24 hour infusion.